Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ: VANI )

1.330 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vivani Medical, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed lower by more than 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Ocean Power Technologies And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed slightly higher on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Charge Enterprises And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed slightly lower on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny... 
Via Benzinga
Topics Stocks
Exposures US Equities
Vivani Medical to Present at the Boulder Peptide Symposium
From Vivani Medical, Inc.
Via Business Wire
Nutex Health And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
From Vivani Medical, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Vivani Medical Reports First Quarter Financial Results and Provides Business Update
From Vivani Medical, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Over $2M Bet On Vivani Medical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny... 
Via Benzinga
Opening Day: VCI Global Jumps In Debut Following Downsized IPO
Shares of Malaysian business consulting company VCI Global jumped 29% to open on Thursday at $5.16 after the company had priced a slimmed-down version of its IPO the day before. 
Via Talk Markets
Opening Day: Tobacco Vape Maker Ispire Goes Public After Downsizing IPO
The vaping products maker Ispire Technology went public this week after downsizing its proposed IPO by 50%. The company had priced its initial public offering of 2.7 million shares at a price to the... 
Via Talk Markets
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vivani Medical, Inc.
Via Business Wire
Opening Day: Singapore's Ohmyhome Makes Nasdaq Debut
Property tech startup Ohmyhome started trading on the Nasdaq on Tuesday, making it the first company headquartered in Singapore to list in the U.S. in 2023. Meanwhile, CBL International opened on March... 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
From Vivani Medical, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Present at the ThinkEquity Investor Conference
From Vivani Medical, Inc.
Via Business Wire
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.